BRIEF-Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700
March 16, 2017 at 08:18 AM EDT
* Alkermes Plc says initiates phase 3 gastrointestinal tolerability study of ALKS 8700 for treatment of multiple sclerosis